The ReProgram

The ReProgram

By Dr. George MurphyScienceLife Sciences
Download on the App Store

The ReProgram episodes

  • Alcohol and Longevity: Is Any Amount Healthy?

    🎬 EPISODE OVERVIEW

    Does alcohol consumption impact longevity? We review the latest clinical evidence to clarify the risks of regular intake.Recent reports from the National Academies of Sciences, Engineering, and Medicine provide a updated look at how alcohol affects long-term health. While many observational studies suggest various correlations, it is critical to distinguish these from direct causation. We analyze the current data to help you understand why popular health claims often struggle to hold up under rigorous scrutiny.We also examine research regarding brain matter volumes from the UK Biobank. When evaluating longevity science, it is easy to conflate preliminary signals with proven clinical outcomes. By focusing on how these studies are designed, we can better assess the actual impact of alcohol on aging and cognitive health. This analysis is for those who prioritize evidence-based longevity science over current trends.If you value longevity science without the hype, subscribe to The ReProgram.

    🔑 KEYWORDS

    Alcohol and longevity, healthy aging, wine, cancer risk, standard drink, J-curve, observational studies, cardiovascular health, brain health.

    📌 KEY TAKEAWAYS

    • A health benefit is a stronger claim than an association in an observational study.

    • Alcohol causes cancer; dose and drinking pattern matter.

    • A generous pour can contain more than one standard drink.

    • Lifetime population estimates are not annual risks or individual predictions.

    • Mortality reviews disagree, and possible benefits must be weighed against established harms.

    • Brain-imaging associations do not prove that one drink causes dementia.

    • If you do not drink, there is no established health reason to start.

    🎙️ THE REPROGRAM PERSPECTIVE

    Enjoyment and a health recommendation are different decisions. We can acknowledge uncertainty, discuss tradeoffs and reduce exposure without shame or exaggerated claims. Heavy, prolonged drinking can cause physical dependence; abrupt withdrawal can be dangerous and may require medical support.

    ⏱️ CHAPTERS

    00:00 Cold open

    01:11 What healthy should mean

    02:34 Cancer risk and alcohol metabolism

    03:48 What counts as one drink?

    04:23 Absolute lifetime risk

    05:36 The J-curve and conflicting mortality evidence

    08:39 The heart is not the whole person

    10:28 The aging brain and everyday function

    11:40 What to do with this information

    13:06 Closing perspective

    💬 JOIN THE CONVERSATION

    Have you been told that wine is good for your health? Which part of the evidence changed how you think about that claim?

    Subscribe to The ReProgram:

    https://www.youtube.com/@ReProgramPodcast

    Longevity Science — Without the Hype.

    And remember, knowledge is power.

    15 min
  • Resveratrol and Longevity: What Does the Human Evidence Show?

    🎬 EPISODE OVERVIEW

    Does resveratrol live up to the longevity hype? We examine the clinical data to see if it actually improves health markers.Research into this supplement often focuses on molecular changes, but we look at how resveratrol impacts real-world patient outcomes. By analyzing studies on cardiovascular health, inflammation, and cognitive function, we distinguish between theoretical benefits and proven clinical results. This scorecard provides a clear framework for evaluating whether the current evidence justifies its use as a longevity intervention.We also compare how different patient groups respond to this compound, highlighting where the data remains inconclusive. Understanding these limitations is essential for anyone trying to separate marketing claims from rigorous science. This analysis is for those who prioritize evidence-based health decisions over popular trends.If you value longevity science without the hype, subscribe to The ReProgram.

    🔑 KEYWORDS

    Resveratrol • Longevity • Human Trials • Healthy Aging • Evidence Scorecard • Supplements

    📌 KEY TAKEAWAYS

    • Changes in selected markers do not establish longer human life.

    • Study population, dose and outcome shape what a finding means.

    • Better cognitive test scores do not demonstrate dementia prevention.

    • Natural origin does not settle safety or medication interactions.

    • Ask what was measured, in whom, and whether the benefit matters.

    🎙️ THE REPROGRAM PERSPECTIVEA molecule can be biologically interesting while its value as an everyday supplement remains uncertain. We should be able to hold both ideas at once. The score can change when the evidence changes.

    ⏱️ CHAPTERS

    00:00 Resveratrol and its claims

    01:09 How the scorecard works

    02:04 Biology and the early animal studies

    03:38 Absorption and exposure

    04:08 Metabolic markers

    05:52 Cardiovascular claims

    06:36 The exercise trial

    07:39 Cognition and dementia distinctions

    09:40 Inflammatory markers

    11:08 Human lifespan

    12:01 Safety and drug interactions

    13:36 The final scorecard and C− grade

    14:40 What better evidence would look like

    14:56 Three questions for any longevity claim

    📝 NOTES AND REFERENCES

    Baur et al. (2006), high-calorie-diet mice:https://doi.org/10.1038/nature05354Miller et al. (2011), mouse lifespan:https://doi.org/10.1093/gerona/glq178Timmers et al. (2011), metabolic study:https://doi.org/10.1016/j.cmet.2011.10.002Yoshino et al. (2012), nonobese women:https://doi.org/10.1016/j.cmet.2012.09.015Sun et al. (2026), umbrella review:https://doi.org/10.1186/s12937-026-01319-5Gliemann et al. (2013), exercise trial:https://pubmed.ncbi.nlm.nih.gov/23878368/Thaung Zaw et al. (2021), cognition crossover trial:https://doi.org/10.1016/j.clnu.2020.08.025Wightman et al. (2026), cognition review:https://doi.org/10.3389/fnut.2026.1839709RESET / JOTROL trial: investigational formulation, not an efficacy result:https://clinicaltrials.gov/study/NCT07592767Zhu et al. (2025), inflammatory markers:https://doi.org/10.3389/fendo.2024.1463027Brown et al. (2010), repeated-dose safety:https://doi.org/10.1158/0008-5472.CAN-10-2364Chow et al. (2010), drug-metabolizing enzymes:https://doi.org/10.1158/1940-6207.CAPR-09-0155

    💬 JOIN THE CONVERSATION

    Which result would most change your view of resveratrol: better function, fewer clinical events, or longer life? Tell us why.

    Subscribe for longevity biology without the hype:https://www.youtube.com/@ReProgramPodcast

    Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

    17 min
  • Can We Reverse Aging in Humans? What the First Results Really Show

    🎬 EPISODE OVERVIEW

    Can we reverse aging? We examine what recent clinical announcements actually prove about the state of human longevity science.Recent reports regarding partial cellular reprogramming have sparked debate about the potential for human age reversal. We break down the distinction between clinical benefit and actual tissue rejuvenation, focusing on what early findings from human trials really indicate. By separating marketing claims from biological reality, we clarify how these interventions affect cellular function.Understanding the limits of current research is vital for anyone interested in healthy aging. We analyze why improvements in specific metrics, such as visual-field tests, do not necessarily equate to a universal reset of the aging process. This assessment provides a grounded look at how we measure progress in the field of longevity and what future experiments must demonstrate to validate these early observations.If you value longevity science without the hype, subscribe to The ReProgram.

    🔑 KEYWORDS

    Partial Reprogramming • ER-100 • OSK • Epigenetics • Glaucoma • Cell Identity • Aging Clocks • Healthspan

    📌 KEY TAKEAWAYS

    • Partial reprogramming aims to change cellular state while preserving specialized function.

    • Early observations in three participants justify further study, not a conclusion of human age reversal.

    • Improvement at visual-field test locations is not a percentage gain in overall vision.

    • Control of gene expression does not establish that every downstream effect is reversible.

    • Durable patient benefit, controlled comparisons, and replication matter more than a younger-looking test alone.

    🎙️ THE REPROGRAM PERSPECTIVE

    A treatment can be a major medical advance without proving that aging has been reversed.The goal is useful function, resilience, and more time living well. Hope and demanding scientific questions belong together.

    ⏱️ CHAPTERS

    00:00 Can we reverse aging—and what would count?

    01:30 The ReProgram opening

    01:38 Partial reprogramming and the evidence cutoff

    02:18 Cell identity and the epigenome

    03:22 Yamanaka factors and pluripotency

    04:23 The challenge of partial reprogramming

    05:16 What mouse studies establish

    06:01 Beyond a universal reset button

    06:51 Vision, OSK, and preclinical evidence

    08:42 ER-100 and early human observations

    10:30 Understanding the visual-field measurement

    11:49 What a small early trial can tell us

    12:50 Variability, learning, and alternative explanations

    15:39 Cell identity and safety

    16:16 Delivery, control, and reversibility

    17:32 Company announcements and complete evidence

    18:05 Clinical benefit versus tissue rejuvenation

    19:56 Broader healthspan claims

    20:35 Aging clocks and meaningful outcomes

    22:27 What would strengthen the evidence?

    24:26 Hope, rigor, and the next experiments

    25:23 Closing thoughts and subscribe

    📝 NOTES AND REFERENCES

    1. Takahashi & Yamanaka. Induction of pluripotent stem cells (Cell, 2006).https://doi.org/10.1016/j.cell.2006.07.024

    2. Ocampo et al. In vivo partial reprogramming (Cell, 2016).https://doi.org/10.1016/j.cell.2016.11.052

    3. Lu et al. Reprogramming to recover youthful epigenetic information and restore vision (Nature, 2020).https://doi.org/10.1038/s41586-020-2975-4

    4. Life Biosciences. Interim company announcement, October 8, 2026; preliminary findings, not a full trial publication.https://www.lifebiosciences.com/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/

    5. ER-100 trial registration, NCT07290244.https://clinicaltrials.gov/study/NCT07290244

    💬 JOIN THE CONVERSATION

    What evidence would convince YOU that a treatment meaningfully rejuvenated human tissue—and what should the next study measure?Subscribe to The ReProgram for longevity biology without the hype.

    https://www.youtube.com/@ReProgramPodcast

    Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

    27 min
  • What Centenarians Reveal About Food and Aging | Dr. Paola Sebastiani

    🎬 EPISODE OVERVIEW

    Can you actually eat like a centenarian to extend your life? We examine the evidence behind dietary habits and aging.Dr. Paola Sebastiani joins us to discuss the complexities of longevity science and why the current diet of someone who has lived to 100 may not reflect the factors that helped them reach that age. We unpack how metabolomics provides clues about physiological decline, while emphasizing that a single blood marker does not establish cause and effect for long-term health.Our conversation addresses common myths regarding protein intake and the role of genetics in exceptional longevity. By analyzing the data from the New England Centenarian Study, we separate biological mechanisms from marketing claims to understand what truly supports healthy aging. We also look at the limitations of biological age tests and why standardization remains a critical challenge in current research.If you value longevity science without the hype, subscribe to The ReProgram for weekly evidence-based breakdowns. What is one belief about food and aging you would be willing to reconsider?

    👤 ABOUT THE SPEAKER

    Dr. Paola Sebastiani is a Professor at Tufts University School of Medicine and Director of the Tufts CTSI Biostatistics, Epidemiology, and Research Design Center. A biostatistician studying genetics and exceptional longevity, she and her group lead data analyses for the New England Centenarian Study.

    Official profile: https://disc.tufts.edu/paola-sebastiani

    🔑 KEYWORDS

    Paola Sebastiani • Centenarians • Nutrition • Metabolomics • Protein • Healthy Aging • Longevity Genetics • Biological Age

    📌 KEY TAKEAWAYS

    • Metabolites offer clues about aging, but a blood marker does not by itself establish cause and effect.

    • A centenarian’s current diet may differ from the diet they followed decades earlier. Longitudinal studies matter.

    • Protein findings from animal studies do not automatically translate to older adults. Sebastiani also cautions against assuming more is always better.

    • Centenarians are a diverse group; no single food or genetic explanation captures every path to exceptional longevity.

    • Sebastiani emphasizes standardization and interpretation when discussing biological-age tests.

    🎙️ THE REPROGRAM PERSPECTIVE

    A longevity headline can turn an association into an apparent prescription. We need to ask who was studied, what was measured, and whether a finding predicts better health or simply accompanies it.The goal is to preserve health, function, and independence—not just chase a number.

    ⏱️ CHAPTERS

    00:00 Should we eat like a centenarian?

    00:58 Introducing Paola Sebastiani

    01:57 An unexpected route into longevity research

    03:56 The Cell Reports paper and metabolomics

    06:04 Nutrition and the dark-chocolate connection

    07:19 Why following people over time matters

    09:01 Essential amino acids and dietary changes

    14:12 What do centenarians eat?

    18:31 Protein restriction versus aging well

    20:39 Protein sources and pumpkin seeds

    22:40 Dietary fats

    23:26 Genes, nutrition, and longevity families

    26:57 Centenarian misconceptions

    27:43 Biological-age tests

    28:57 Healthspan and longevity interventions

    30:05 The unresolved genetics of longevity

    31:08 Activity tracking and personal habits

    33:21 What aging well means

    34:20 Closing thoughts

    📝 NOTES AND REFERENCES

    1. Sebastiani P et al. Metabolite signatures of chronological age, aging, survival, and longevity. Cell Reports (2024);43(11):114913.https://doi.org/10.1016/j.celrep.2024.114913Open-access paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC11656345/

    💬 JOIN THE CONVERSATION

    What is one belief about food and aging you would be willing to reconsider?

    Subscribe to The ReProgram for more conversations about livingwell.

    https://www.youtube.com/@ReProgramPodcast

    Longevity Biology Without the Hype

    Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

    36 min
  • Omega-3 Fish Oil: What Does the Evidence Actually Support?

    🎬 EPISODE OVERVIEW

    Does your fish oil capsule deserve its reputation? In Episode 31, I review omega-3s for heart health, cognition, and healthy aging, then give five evidence scores and an overall C+.We examine VITAL, REDUCE-IT, STRENGTH, newer DHA research, aging clocks, and safety. Eating fish, taking supplements, and using prescription omega-3s are different questions.

    🔑 KEYWORDS

    Omega-3 • Fish Oil • EPA • DHA • Triglycerides • Cognition • Aging Clocks • Atrial Fibrillation • Longevity

    📌 KEY TAKEAWAYS

    • Triglyceride lowering: 5/5 at studied therapeutic doses.

    • Routine cardiovascular prevention in generally healthy adults: 2/5. Prescription EPA in selected high-risk patients is a separate clinical decision.

    • Preventing cognitive decline in generally healthy older adults: 1/5.

    • Epigenetic aging clocks: 2/5. Small changes in clock estimates do not establish longer life.

    • Extending human lifespan through routine supplementation: 1/5.

    • Overall: C+ for routine OTC fish oil as a healthy-aging intervention; this is my assessment, not a mathematical average. Dose, formulation, and baseline risk matter.

    🎙️ THE REPROGRAM PERSPECTIVE

    A biological mechanism or improved test result is a starting point. Ask whether the evidence shows better health, function, or survival in people like you. Educational discussion; understand prescribed treatment with your clinician before making changes.

    ⏱️ CHAPTERS

    00:00 What has fish oil earned?

    00:55 The Scorecard framework

    01:16 Fish, supplements, and prescription products

    01:56 Read the EPA and DHA label

    02:27 Triglycerides: the strongest evidence

    03:43 VITAL and heart prevention

    04:39 REDUCE-IT and prescription EPA0

    5:50 STRENGTH and conflicting results

    07:08 Brain health and the DHA trials

    08:34 DO-HEALTH and aging clocks

    09:59 Heart-rhythm risk and interactions

    11:37 Five claims, five scores

    13:22 The C+ verdict and its limits

    14:27 Questions to ask about your supplement

    15:31 Closing perspective

    💬 JOIN THE CONVERSATION

    If you take fish oil, what benefit are you hoping for—and does the evidence match that goal?

    Subscribe to The ReProgram: https://www.youtube.com/@ReProgramPodcast

    Longevity Biology Without the Hype.

    Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

    17 min
  • Can We Really Measure and Reverse Aging? | Steve Horvath

    🎬 EPISODE OVERVIEW

    Can a younger clock score translate into better health?In Episode 30, I sit down with Dr. Steve Horvath to explore epigenetic clocks, biological-age claims, and his vision for rejuvenation.

    We discuss why there are so many clocks, what stands between research and patient care, prevention, and why progress may come one organ at a time

    .👤 ABOUT THE SPEAKER

    Dr. Steve Horvath is Professor of Medicine and Director of Aging Biology Research at UCLA’s David Geffen School of Medicine. A geroscientist and biostatistician, he developed the influential 2013 multi-tissue DNA methylation clock.Lab profile: https://horvathaginglab.org/

    🔑 KEYWORDS

    Steve Horvath • Epigenetic Clocks • DNA Methylation • Biological Age • Rejuvenation • Prevention • Aging Biomarkers • Geroscience

    📌 KEY TAKEAWAYS

    • Different aging clocks can produce different results. Horvath argues for transparent reporting across multiple clocks.

    • Dramatic age-reversal claims deserve scrutiny; a younger test result needs meaningful interpretation.

    • Horvath sees promise in clinical use, while emphasizing that routine patient care is not there yet.

    • Rejuvenation is connected to prevention: the aim is to preserve health before disease develops.

    • A realistic path may focus on individual organs rather than a single treatment for the entire body.

    🎙️ THE REPROGRAM PERSPECTIVE

    Better measurement can sharpen the questions we ask about aging. The next challenge is connecting those measurements to outcomes that matter to people.Our focus: what changed, how reliably was it measured, and what does it mean for health and function?

    ⏱️ CHAPTERS

    00:00 Can we measure and reverse aging?

    00:51 Introducing Steve Horvath

    01:40 Reinventing a research career

    05:28 Why are there so many aging clocks?

    07:51 Bringing clocks into clinical practice

    09:16 Evaluating age-reversal claims

    11:31 Rejuvenation and prevention

    14:37 What does rejuvenation mean?

    16:26 One organ at a time

    18:36 Lifestyle, testing, and perspective

    20:57 Closing thoughts

    📝 NOTES AND REFERENCES

    Related papers featured in the edit:

    1. Horvath S. DNA methylation age of human tissues and cell types. Genome Biology (2013).https://doi.org/10.1186/gb-2013-14-10-r115

    2. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics (2018).https://doi.org/10.1038/s41576-018-0004-3

    3. Lu Y et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature (2020).https://doi.org/10.1038/s41586-020-2975-4The Lu study is preclinical mouse research, not evidence of whole-body age reversal in humans.

    💬 JOIN THE CONVERSATION

    What would convince you that an intervention truly rejuvenates: a younger clock score, better organ function, or both?

    Subscribe to The ReProgram for longevity biology without the hype.https://www.youtube.com/@ReProgramPodcast

    Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

    22 min
  • What Long-Lived Animals Teach Us About Aging | Dr. Steve Austad

    🎬 EPISODE OVERVIEW

    Why do some animals live so much longer than others—and what can they teach us about healthier human aging?In Episode 29 of The ReProgram, I sit down with Dr. Steve Austad to explore nature’s longevity clues, why women tend to outlive men, and what would count as convincing evidence that an intervention slows aging.We discuss aging “speedometers,” the difference between lifespan and healthspan, the case for funding geroscience, and how to evaluate biological-age claims without losing sight of enjoying life.

    👤 ABOUT THE SPEAKER

    Dr. Steven N. Austad is a Distinguished Professor and Protective Life Endowed Chair in Healthy Aging Research at the University of Alabama at Birmingham, and Scientific Director of the American Federation for Aging Research. His research explores the comparative biology of aging, using differences among species to understand longevity and identify potential ways to preserve human health.Official profile: https://www.uab.edu/icar/about/icar-leadership/steven-n-austad-phd

    🔑 KEYWORDS

    Longevity • Comparative Biology • Steve Austad • Healthspan • Aging Rate Indicators • Biological Age • Geroscience • Sex Differences • DunedinPACE

    📌 KEY TAKEAWAYS

    • Long-lived animals offer clues about aging biology and potential directions for human research.

    • A finding in animals is a starting point; demonstrating a meaningful benefit in people requires further testing.

    • Measuring biological age and measuring the pace of aging are different questions. A change in a test result alone does not prove that an intervention slows aging.

    • Healthspan puts the focus on maintaining function and quality of life.

    • Evaluating longevity claims means asking what was measured, what changed, and whether the evidence supports the conclusion.

    🎙️ THE REPROGRAM PERSPECTIVE

    Nature shows that the pace of aging varies enormously across species. Understanding the biology behind those differences could reveal ways to preserve human health.For The ReProgram, the next step is to connect those clues to rigorous tests: does an intervention produce a reproducible improvement in function, resilience, or healthy years of life? Aging measurements are valuable when they help answer that question. The goal is more time living well, with evidence strong enough to guide our choices.

    ⏱️ CHAPTERS

    00:00 What nature can teach us

    00:28 The ReProgram

    00:36 Introducing Steve Austad

    01:23 Opossums and the origins of an aging scientist

    02:44 What is aging?

    03:43 Evolution and longevity

    04:46 Learning from long-lived animals

    07:24 Why women tend to live longer

    12:03 What would count as evidence of slower aging?

    13:13 From animal findings to human benefits

    14:31 Aging clocks versus aging speedometers

    18:49 Lifespan and healthspan

    19:44 Lightning round: the XPRIZE

    21:19 Funding aging research

    22:43 Evaluating biological-age claims

    24:01 Enjoying life while studying longevity

    25:13 Closing thoughts

    📝 NOTES AND REFERENCES

    1. Austad SN, Kaeberlein M, Miller RA. Aging rate indicators and the search for anti-aging drugs. Frontiers in Science (2026).https://doi.org/10.3389/fsci.2026.1821393

    2. Belsky DW et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife (2022);11:e73420.https://doi.org/10.7554/eLife.73420Clarification: DunedinPACE uses DNA methylation to estimate the pace of aging. The on-screen explanation clarifies the interview’s reference to an RNA marker.

    3. XPRIZE Healthspan — official competition information:https://www.xprize.org/competitions/healthspan

    💬 JOIN THE CONVERSATION

    What would convince YOU that a treatment truly slows aging: a biological-age test, better physical function, or something else?

    Tell us which result matters most—and why.If you value longevity science without the hype, subscribe to The ReProgram.https://www.youtube.com/@ReProgramPodcast

    Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

    26 min
  • Can We Slow Human Aging? What Would Count as Proof? | Dr. Nik Schork

    🎬 EPISODE OVERVIEW

    The Longevity Consortium is mapping the biology of aging. We review the NIH-funded research aiming to delay chronic disease.The NIH-supported Longevity Consortium is a massive effort to understand the biology of aging to reduce risks of cancer, dementia, and frailty. We examine their five core focus areas, ranging from exceptional longevity cohorts to candidate drug screening. Dr. Nik Schork and Dr. George Murphy break down the current strategy for targeting age-related decline.This initiative represents a distinct pivot in geroscience research, moving beyond single-pathway hypotheses to look at systemic biological markers. We analyze the scope of these projects to see which are likely to yield clinical outcomes and which remain preliminary explorations. Understanding the biology of aging remains a complex challenge, but this consortium provides a structural framework for how we might eventually mitigate chronic disease.

    🔑 KEYWORDS

    Longevity • Healthspan • Aging Biology • NIH • NIA • Longevity Consortium • Nik Schork • Centenarians • Human Cell Models • Geroscience

    📌 KEY TAKEAWAYS

    ◆ Healthspan and lifespan are related goals, but improving a biological measurement is not the same as proving that people live longer.

    ◆ Exceptional longevity may reflect protective biology alongside disease-risk variants, as well as behavior and environmental exposures.

    ◆ The five projects connect discovery with functional testing. A genetic association still needs a biological explanation and follow-up experiments.

    ◆ Human cell models help isolate a signal; animal studies and human research test whether it matters in a more complex system.

    ◆ Public funding supports collaboration across disciplines and exploratory work that may not begin with a single commercial product.

    ◆ Shared aging mechanisms could offer opportunities to address multiple diseases. That is a research goal, not a claim that a proven universal treatment exists.

    ◆ A critical approach to evidence matters when evaluating claims about measuring or reversing biological age.

    🎙️ THE REPROGRAM PERSPECTIVE

    Longevity Biology Without the Hype. The important question is not simply whether an intervention changes a marker, but whether it produces a meaningful, reproducible benefit for people. This conversation follows the research pathway; it does not present a finished anti-aging treatment.⏱️

    CHAPTERS

    00:00 Can we slow aging?

    01:08 Meet Dr. Nik Schork

    02:01 From philosophy to longevity science

    03:53 What is the Longevity Consortium?

    05:24 Healthspan versus lifespan

    06:31 Why team science matters07:55 Project 1: Predicting human longevity

    09:23 Project 2: Lessons from long-lived species

    12:46 Project 3: Centenarians and resilience

    14:50 Disease-risk genes and exceptional longevity

    16:20 Project 4: From genes to candidate drugs

    19:04 Project 5: Testing ideas in human cells

    21:42 Connecting a discovery across the consortium

    24:45 The challenge of proving human benefit

    26:38 What public funding makes possible

    29:12 Shared aging mechanisms and the public payoff

    32:13 What success could look like

    35:02 Lightning round: Can aging biology be modified?

    36:12 Misconceptions about publicly funded science

    37:24 How to evaluate longevity claims

    39:13 How the science shapes Nik’s own health choices

    41:50 Closing the conversation

    42:48 The ReProgram takeaway

    📝 SELECTED NOTES AND REFERENCES

    1. Longevity Consortium overview. Official description of the research program and its integrated approach.https://www.longevityconsortium.org/overview/

    2. Longevity Consortium projects and resources. Explore the five projects and their leadership. https://www.longevityconsortium.org/

    ▶

    Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

    44 min
  • Can Magic Mushrooms Change How We Age? The Psilocybin Scorecard

    🎬 EPISODE OVERVIEW

    Could the compound in magic mushrooms influence how we age? Psilocybin research is producing intriguing findings, but changing brain activity, treating depression and extending human life are very different claims.In Episode 27, Dr. George Murphy puts psilocybin through The ReProgram Scorecard. He examines experiments in human cells and aged mice, brain imaging and plasticity studies, inflammatory markers, and clinical research on depression.The episode also explores preliminary Parkinson’s and Alzheimer’s reports, why a change in a biomarker is not the same as preventing disease, and what it would take to establish a meaningful benefit for older adults.The verdict: psilocybin deserves serious investigation. The evidence discussed does not establish human life extension or dementia prevention. Its strongest clinical argument remains mental health treatment in carefully supervised settings.

    🔑 KEYWORDS

    Psilocybin • Psilocin • Psychedelics • Longevity • Brain Plasticity • Depression • Inflammation • Cognitive Aging • ReProgram Scorecard

    📌 KEY TAKEAWAYS

    • The longevity headline needs context. More cell divisions in a dish and improved mouse survival at a study endpoint do not demonstrate longer human life.

    • Brain changes are measurable. Plasticity and altered network coordination do not establish a universal neurotransmitter reset or a rejuvenated brain.• Inflammation findings vary. The marker, population and timing matter; sustained clinical benefit remains an open question.

    • Preliminary observations cannot establish dementia prevention. Small uncontrolled studies and an Alzheimer’s case report provide research questions, not proof of disease reversal.

    • Mental health benefits deserve their own assessment. Randomized evidence is encouraging, while durability, patient selection, support and adverse effects still matter.

    • Evidence grades are claim specific. A strong plasticity score cannot fill the evidence gap for dementia prevention or human life extension.

    🎙️ THE REPROGRAM PERSPECTIVE

    Psilocybin’s potential is worth investigating. The next step is to establish which changes help, who benefits, how long benefits last, and what they cost in risk.Brain plasticity and network change: 4/5Mental health benefit in supervised treatment: 3/5Reducing inflammation: 2/5Preventing cognitive decline: 1/5Extending human lifespan: 1/5These are evidence grades, not treatment recommendations. They are not averaged into an overall score. The episode does not establish a longevity dosing regimen or justify self-directed use.

    ⏱️ CHAPTERS

    00:00 Could psilocybin change how we age?

    01:12 Five different claims

    01:54 Cells mice and the longevity headline

    03:19 What brain plasticity actually means

    05:06 Human brain changes and study limitations

    05:52 Neurotransmitters and the chemical reset claim

    07:00 Inflammation signals and conflicting findings

    09:00 Cognitive decline Parkinson's and Alzheimer's

    10:58 Depression benefits durability and risks

    11:59 The five part ReProgram Scorecard

    13:26 What would change the evidence grades

    14:03 Safety and the final verdict

    📝 SELECTED NOTES AND REFERENCES1. Psilocybin treatment extends cellular lifespan and improves survival of aged mice. npj Aging. 2025. Cell and aged female mouse experiments behind the longevity discussion.https://doi.org/10.1038/s41514-025-00...

    2. Psilocybin desynchronizes the human brain. Nature. 2024. Repeated imaging of brain network changes in seven healthy adults.https://doi.org/10.1038/s41586-024-07...

    3. Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks. Cell. Published online December 2025. Mouse research on activity-dependent plasticity.https://doi.org/10.1016/j.cell.2025.1...

    If you value longevity science without the hype, subscribe to The ReProgram.

    Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

    16 min
  • Ozempic Extended Mouse Lifespan. Does That Change the Longevity Scorecard?

    ReProgram Episode 26: GLP-1 Drugs for Longevity

    🎬 EPISODE OVERVIEW

    A drug millions of people already take extended median lifespan by approximately 12% in older female mice. Does that change the case for GLP-1 drugs as longevity therapies?In this update, Dr. George Murphy reopens The ReProgram Scorecard to examine a new Nature study of late-life semaglutide treatment. He explores the survival findings, improvements in physical and cognitive performance, and the questions that determine how broadly we should interpret the results.How long did the control animals live? How much of the benefit came from eating less? What can a study conducted in females tell us about males—and ultimately humans?The episode also examines new research connecting calorie restriction with DNA mutation accumulation, the challenge of translating mouse biology into human outcomes, and the lessons from semaglutide’s Alzheimer’s trials.The updated assessment: stronger animal evidence and more compelling questions, while the overall grade remains B+.

    🔑 KEYWORDS

    GLP-1 • Semaglutide • Ozempic • Wegovy • Longevity • Healthy Aging • Calorie Restriction • Somatic Mutations • Healthspan • ReProgram Scorecard

    📌 KEY TAKEAWAYS

    • The survival finding deserves attention. Median lifespan increased from 742 to 834 days when semaglutide treatment began at 20 months of age and continued throughout life.

    • The calorie restriction question remains open. Selected functional outcomes were compared with matched calorie restriction; lifespan was not.

    • A benefit in females does not establish a female-specific effect. Males were not tested.

    • Historical controls provide context. They cannot replace the controls studied alongside treated animals; replication remains essential.

    • The DNA connection is a hypothesis. New calorie restriction research raises questions about mutation accumulation, but does not establish that semaglutide reduces somatic mutations.

    • Human outcomes still determine the grade. Strength, mobility, nutrition, cognition, and independence remain central to evaluating longevity interventions.

    🎙️ THE REPROGRAM PERSPECTIVE

    This study strengthens the reason to investigate GLP-1 therapies in aging. It also sharpens the experiments we need next: replication, direct survival comparisons with calorie restriction, testing both sexes, and meaningful human outcomes.Mechanistic plausibility remains 4.5/5. Human evidence remains 3.5/5. The overall grade stays B+.My interest has increased. My standard of evidence has not changed.

    ⏱️ CHAPTERS

    00:00 A 12% Lifespan Increase: What Does It Mean?

    00:36 Revisiting GLP1 Therapies and Longevity

    01:12 The New Nature Study

    01:28 How Semaglutide Works

    01:57 The Survival Result

    03:10 The Importance of Starting Age in Treatment

    03:57 The Control-Lifespan Debate

    05:33 Sex Differences in Longevity Research

    06:26 The Calorie Restriction Question

    07:35 Calorie Restriction & DNA Mutations

    09:01 Translating Mouse Findings to Humans

    10:00 Lessons from the Alzheimer’s Trials

    11:02 The Updated ReProgram Scorecard

    📝 NOTES AND REFERENCES

    1. Feng Y, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 2026;657:469–476. The central study discussed in this episode.https://www.nature.com/articles/s41586-026-10940-7

    2. Grońska-Pęski M, et al. Caloric restriction modulates genome-wide somatic mutation in mice. Cell. 2026. The calorie restriction and mutation study discussed in the episode.https://doi.org/10.1016/j.cell.2026.08.013

    3. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392–395. A landmark comparison showing that late-life intervention can extend lifespan in both sexes.https://www.nature.com/articles/nature08221

    If you value longevity science without the hype, subscribe to The ReProgram.

    Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

    13 min

About The ReProgram

From the publisher's feed

The ReProgram is dedicated to exploring how we can extend the healthy human lifespan through science and self-understanding. Hosted by Dr. George Murphy, each episode dives into the rapidly evolving fields of aging biology, longevity, regenerative medicine, and geroscience.